Form S-8 Axsome Therapeutics,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Axsome Therapeutics (AXSM) PT Lowered to $130 at RBC Capital
August 6, 2024 6:42 AM EDTRBC Capital analyst Leonid Timashev lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $130.00 (from $131.00) while maintaining a Outperform rating.
The analyst comments "This morning AXSM reported 2Q24 earnings where we saw continued growth for Auvelity and major... More



